These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39009541)

  • 1. [Heparin Resistance After Administration of Andexanet Alfa:Report of a Case].
    Aratame A; Baba T; Minamimura H; Nishimoto Y; Nangoya R
    Kyobu Geka; 2024 Jun; 77(6):454-456. PubMed ID: 39009541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban.
    Eche IM; Elsamadisi P; Wex N; Wyers MC; Brat GA; Cunningham K; Bauer KA
    Pharmacotherapy; 2019 Aug; 39(8):861-865. PubMed ID: 31251821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet Alfa: First Global Approval.
    Heo YA
    Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
    Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
    Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
    Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
    Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report.
    Jenniches D; Kerns AF; DelBianco J; Stripp MP; Philp AS
    Am J Health Syst Pharm; 2023 Nov; 80(23):1722-1728. PubMed ID: 37688311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology.
    Angelillo-Scherrer A; Casini A; Studt JD; Gerber B; Alberio LA; Fontana P
    Swiss Med Wkly; 2023 Jul; 153():40113. PubMed ID: 37499160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report.
    Brenner B; Guerra J; Williams C; Littlewood K; Kern J; Tanaka K; McNeil JS; Mangunta V
    A A Pract; 2022 Nov; 16(11):e01636. PubMed ID: 36599062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andexanet alfa for the reversal of factor Xa inhibitors.
    Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
    Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world utilization of andexanet alfa.
    Brown CS; Scott RA; Sridharan M; Rabinstein AA
    Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
    Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
    Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists.
    Rodriguez V; Stanek J; Kerlin BA; Dunn AL
    Clin Appl Thromb Hemost; 2022; 28():10760296221078842. PubMed ID: 35275498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
    Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
    J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
    Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
    Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report.
    Flaherty D; Connors JM; Singh S; Sylvester KW; Rimsans J; Cornella L
    A A Pract; 2019 Oct; 13(7):271-273. PubMed ID: 31265446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.